However, the suitability of NUAK1 as a potential therapeutic target in PDAC, or other cancers, must ultimately be weighed against the potential toxicity arising from the herein‐described requirement for NUAK1 to maintain genomic integrity through control of centrosome replication. This evidence concerns the gene NUAK1 and cancer.